Morgan Stanley Maintains Equal-Weight on NeuroPace, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri has maintained an Equal-Weight rating on NeuroPace (NASDAQ:NPCE) and increased the price target from $8 to $9.
December 04, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on NeuroPace and raised the price target from $8 to $9, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Morgan Stanley suggests a positive sentiment towards NeuroPace's stock performance in the short term. This could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100